Passage Bio delivered promising data in 2024 showing durable progranulin expression and completed development and scale-up of a high-productivity, suspension-based manufacturing process. The company benefits from strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program and partnership agreements with Catalent Maryland.
Cyborg Score Rationale
Passage Bio reported significant positive updates on PBFT02 clinical trial with promising interim results including robust progranulin elevation and improvement in disease progression biomarkers. Cash runway extends into Q1 2027 with $52.8M in cash and equivalents as of September 2025. Strong analyst support with recent analyst initiations and upgrades, consensus "Strong Buy" rating with $34.50 average price target as of February 2026.
Top Insights
Dose 2 PBFT02 is 50% lower than Dose 1, with expectations to report 12-month data from Dose 1 and interim safety data from Dose 2 in H2 2025
Actively enrolling patients in Cohorts 3-4 of upliFT-D study targeting FTD-GRN and FTD-C9orf72 variants with protocol amendments for broader early-stage enrollment
FDA-aligned manufacturing process produced batch yielding >1,000 doses at >90% purity and >70% full capsids, demonstrating scalability
Completed 1-for-20 reverse stock split in July 2025, reducing shares from 62.4M to 3.1M to maintain Nasdaq compliance
Named Competitors
Gene Therapies for Rare Neurological Diseases — Focused on genetic medicines for rare neurological conditions
AAV Gene Therapy Platform — Develops gene therapies for severe rare conditions
AAV Gene Therapy Platform — Develops gene therapies for severe rare neurological conditions
Recent Developments
(November 2025) Reported positive interim data from upliFT-D study Cohort 2 with robust progranulin elevation and biomarker improvement
(November 2025) Announced FDA alignment on analytical comparability for suspension-based PBFT02 manufacturing process